Skip to main content
TipRanks
Go Ultimate75% OFF

Endonovo Therapeutics (ENDV) AI Stock Analysis

24 Followers
ENDV

Endonovo Therapeutics

(Other OTC:ENDV)

Select Model
Rating:35Underperform
Action:N/A
Date:01/02/25

Endonovo Therapeutics' stock score is heavily impacted by its poor financial performance and lack of positive technical indicators. The company's financial instability, highlighted by negative equity and inconsistent cash flow, presents significant risks. Valuation metrics further reflect these challenges, and the absence of earnings call data adds to uncertainty. The overall score reflects these concerns, suggesting a need for caution and strategic restructuring to improve long-term prospects.

Positive Factors
Innovative Product OfferingEndonovo's focus on non-invasive, bioelectronic therapies positions it well in the growing field of regenerative medicine, offering a unique solution for pain management and recovery.
Negative Factors
Financial InstabilityNegative equity and high liabilities indicate financial distress, posing risks to long-term viability and limiting strategic options.

Endonovo Therapeutics (ENDV) vs. SPDR S&P 500 ETF (SPY)

Not enough price history over this period.

Market Cap
$31.88K
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.1
Beta (1Y)
280.11
Revenue Growth
―
EPS Growth
48.00%
Country
US
Employees
1
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Endonovo Therapeutics Business Overview & Revenue Model

Company Description

Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is S...

How the Company Makes Money

Endonovo Therapeutics primarily generates revenue through the sale and lease of its SofPulse devices to hospitals, clinics, and other healthcare facilities. The company's revenue model includes direct sales, leasing arrangements, and service agreemen...

Endonovo Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ENDV against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NUWENUWE47Neutral$2.65M-0.00-408.34%―10.28%95.85%
BJDXBJDX44Neutral$2.92M-0.11-113.80%――95.46%
DRMADRMA40Underperform$3.06M-0.19-189.68%――83.79%
SCNISCNI39Underperform$541.29K0.00-23.86%―143.06%94.98%
PRFXPRFX37Underperform$2.38M-0.07-72.87%―――
ENDVENDV35Underperform$180.76K-0.087.76%――48.00%

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%NUWESCNIPRFXDRMABJDXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ENDV and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ENDVEndonovo Therapeutics, Inc.―――
NUWENuwellis, Inc.4.90-767.48-99.37%
SCNIScinai Immunotherapeutics Ltd. Sponsored Adr0.40-9.22-95.84%
PRFXPainreform Ltd.0.78-3.64-82.30%
DRMADermata Therapeutics, Inc.0.62-2.22-78.13%
BJDXBluejay Diagnostics, Inc.2.61-20.27-88.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jan 02, 2025